RIPK1 and neoplasm: Interestingly, intratumoral administration of LD4172 improved RIPK1 degradation in the tumors (Supplementary Fig. 7), suggesting that the incomplete degradation of RIPK1 in tumors via i.p. injections may be attributed to poor penetration and/or accumulation of LD4172 in tumor tissues.